Treatment delivered through a device

Some conditions respond to structured behavioural intervention as well as to medication, and software can deliver that intervention at a fraction of the cost of a clinician. The clinical evidence for several such products is real. The payment infrastructure has been the problem.

Historically the category over promised, with several high profile companies failing after securing clearance but never securing reimbursement. That history makes investors and clinicians cautious.

The structural driver is chronic disease cost plus clinician scarcity. Conditions requiring continuous management consume enormous resources, and there are not enough clinicians to deliver behavioural intervention at the needed scale.

The technology layer spans prescription digital therapeutics with regulatory clearance, remote monitoring devices feeding clinical data continuously, algorithms that flag deterioration early, and the integration into electronic records that makes clinicians actually use the output.

Adoption economics require a reimbursement code and a prescriber willing to use it. Both exist for a growing set of indications, but usage lags availability considerably.

The beneficiaries include digital therapeutic developers with clearance and coverage, remote monitoring device makers, platform companies aggregating multiple products, and the health systems reducing readmissions.

The value chain runs from developer through prescriber and pharmacy benefit to patient. The prescribing step is the friction, since clinicians must remember a product exists.

The overlooked layer includes remote monitoring hardware, data integration vendors connecting devices to records, specialty pharmacy channels handling digital prescriptions, and the clinical evidence generation firms.

Competitive dynamics favour products with both clearance and coverage, which is a much shorter list than products with clearance alone.

Risks: the category has produced notable failures, reimbursement is inconsistent, clinician adoption is slow, and patient engagement drops sharply after initial use.

What to watch: reimbursement codes actually being billed, prescriber adoption rates, engagement and completion data, and health system programme launches.